Treatments for severe pulmonary hypertension
- 1 January 1999
- journal article
- review article
- Published by Elsevier BV in The Lancet
- Vol. 353 (9150), 338-340
- https://doi.org/10.1016/s0140-6736(98)00330-4
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertensionEuropean Respiratory Journal, 1998
- Action of fenfluramine on voltage- gated K+ channels in human pulmonary-artery smooth-muscle cellsThe Lancet, 1998
- CELLULAR AND MOLECULAR MECHANISMS OF PULMONARY VASCULAR REMODELINGAnnual Review of Physiology, 1997
- Localization of the gene for familial primary pulmonary hypertension to chromosome 2q31–32Nature Genetics, 1997
- Vascular Endothelial Growth Factor in Pulmonary HypertensionAnnals of the New York Academy of Sciences, 1996
- Appetite-Suppressant Drugs and the Risk of Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1995
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993
- An Imbalance between the Excretion of Thromboxane and Prostacyclin Metabolites in Pulmonary HypertensionNew England Journal of Medicine, 1992